-
1
-
-
0032554688
-
Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial
-
Sacks FM, Moye LA, Davis BR, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation. 1998 ; 97: 1446-1452
-
(1998)
Circulation
, vol.97
, pp. 1446-1452
-
-
Sacks, F.M.1
Moye, L.A.2
Davis, B.R.3
-
2
-
-
0034647158
-
Statins and risk of coronary heart disease
-
LaRosa JC. Statins and risk of coronary heart disease. JAMA. 2000 ; 283: 2935-2936
-
(2000)
JAMA
, vol.283
, pp. 2935-2936
-
-
Larosa, J.C.1
-
3
-
-
2942627194
-
Pharmacogenetic study of statin therapy and cholesterol reduction
-
Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP, Ridker PM. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA. 2004 ; 291: 2821-2827
-
(2004)
JAMA
, vol.291
, pp. 2821-2827
-
-
Chasman, D.I.1
Posada, D.2
Subrahmanyan, L.3
Cook, N.R.4
Stanton, V.P.5
Ridker, P.M.6
-
4
-
-
41149174566
-
Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment
-
Krauss RM, Mangravite LM, Smith JD, et al. Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation. 2008 ; 117: 1537-1544
-
(2008)
Circulation
, vol.117
, pp. 1537-1544
-
-
Krauss, R.M.1
Mangravite, L.M.2
Smith, J.D.3
-
5
-
-
49149095635
-
Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin
-
Medina MW, Gao F, Ruan W, Rotter JI, Krauss RM. Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation. 2008 ; 118: 355-362
-
(2008)
Circulation
, vol.118
, pp. 355-362
-
-
Medina, M.W.1
Gao, F.2
Ruan, W.3
Rotter, J.I.4
Krauss, R.M.5
-
6
-
-
77649197488
-
Association of the functional variant in the 3-hydroxy-3-methylglutaryl- coenzyme a reductase gene with low-density lipoprotein-cholesterol in Japanese
-
Hiura Y, Tabara Y, Kokubo Y, et al. Association of the functional variant in the 3-hydroxy-3-methylglutaryl-coenzyme a reductase gene with low-density lipoprotein-cholesterol in Japanese. Circ J. 2010 ; 74: 518-522
-
(2010)
Circ J
, vol.74
, pp. 518-522
-
-
Hiura, Y.1
Tabara, Y.2
Kokubo, Y.3
-
7
-
-
33644609683
-
Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: The Cholesterol and Pharmacogenetics (CAP) Study
-
Simon JA, Lin F, Hulley SB, et al. Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study. Am J Cardiol. 2006 ; 97: 843-850
-
(2006)
Am J Cardiol
, vol.97
, pp. 843-850
-
-
Simon, J.A.1
Lin, F.2
Hulley, S.B.3
-
8
-
-
19744373433
-
Best-selling human medicines 2002-2004
-
Maggon K. Best-selling human medicines 2002-2004. Drug Discov Today. 2005 ; 10: 739-742
-
(2005)
Drug Discov Today
, vol.10
, pp. 739-742
-
-
Maggon, K.1
-
9
-
-
25844530136
-
Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers
-
Chung JY, Cho JY, Yu KS, et al. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther. 2005 ; 78: 342-350
-
(2005)
Clin Pharmacol Ther
, vol.78
, pp. 342-350
-
-
Chung, J.Y.1
Cho, J.Y.2
Yu, K.S.3
-
10
-
-
33646198187
-
Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin
-
Igel M, Arnold KA, Niemi M, et al. Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clin Pharmacol Ther. 2006 ; 79: 419-426
-
(2006)
Clin Pharmacol Ther
, vol.79
, pp. 419-426
-
-
Igel, M.1
Arnold, K.A.2
Niemi, M.3
-
12
-
-
0038209381
-
Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics
-
Nishizato Y, Ieiri I, Suzuki H, et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther. 2003 ; 73: 554-565
-
(2003)
Clin Pharmacol Ther
, vol.73
, pp. 554-565
-
-
Nishizato, Y.1
Ieiri, I.2
Suzuki, H.3
-
13
-
-
72849141790
-
Transporter pharmacogenetics and statin toxicity
-
Niemi M. Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther. 2010 ; 87: 130-133
-
(2010)
Clin Pharmacol Ther
, vol.87
, pp. 130-133
-
-
Niemi, M.1
-
14
-
-
49949104757
-
SLCO1B1 variants and statin-induced myopathy-a genomewide study
-
Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med. 2008 ; 359: 789-799
-
(2008)
N Engl J Med
, vol.359
, pp. 789-799
-
-
Link, E.1
Parish, S.2
Armitage, J.3
-
15
-
-
34548009561
-
SLCO1B1 521T->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients
-
Zhang W, Chen BL, Ozdemir V, et al. SLCO1B1 521T->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients. Br J Clin Pharmacol. 2007 ; 64: 346-352
-
(2007)
Br J Clin Pharmacol
, vol.64
, pp. 346-352
-
-
Zhang, W.1
Chen, B.L.2
Ozdemir, V.3
-
16
-
-
84860181689
-
-
New York, NY: Pfizer Inc;
-
New York, NY: Pfizer Inc ;
-
-
-
-
17
-
-
25844458977
-
Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment
-
Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther. 2005 ; 78: 330-341
-
(2005)
Clin Pharmacol Ther
, vol.78
, pp. 330-341
-
-
Lee, E.1
Ryan, S.2
Birmingham, B.3
-
18
-
-
0025345124
-
Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol
-
Reihner E, Rudling M, Stahlberg D, et al. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N Engl J Med. 1990 ; 323: 224-228
-
(1990)
N Engl J Med
, vol.323
, pp. 224-228
-
-
Reihner, E.1
Rudling, M.2
Stahlberg, D.3
-
19
-
-
77949906521
-
Atorvastatin increases expression of low-density lipoprotein receptor mRNA in human circulating mononuclear cells
-
Pocathikorn A, Taylor RR, Mamotte CD. Atorvastatin increases expression of low-density lipoprotein receptor mRNA in human circulating mononuclear cells. Clin Exp Pharmacol Physiol. 2010 ; 37: 471-476
-
(2010)
Clin Exp Pharmacol Physiol
, vol.37
, pp. 471-476
-
-
Pocathikorn, A.1
Taylor, R.R.2
Mamotte, C.D.3
-
20
-
-
77953962940
-
Combined influence of LDLR and HMGCR sequence variation on lipid-lowering response to simvastatin
-
Mangravite LM, Medina MW, Cui J, et al. Combined influence of LDLR and HMGCR sequence variation on lipid-lowering response to simvastatin. Arterioscler Thromb Vasc Biol. 2010 ; 30: 1485-1492
-
(2010)
Arterioscler Thromb Vasc Biol
, vol.30
, pp. 1485-1492
-
-
Mangravite, L.M.1
Medina, M.W.2
Cui, J.3
|